2020 American Transplant Congress
Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
*Purpose: To evaluate development of de novo donor specific antibodies (dnDSA) in Renal Transplant Recipients (RTR) with immunosuppression (IS) modulation due to BK viremia (BKV)…2020 American Transplant Congress
Clinical Outcomes Associated with Long-Term Exposure to Airborne Particulate Pollution in Kidney Transplant Recipients
*Purpose: We aimed to evaluate the relationship of 10-μm particulate matter (PM10) with the risk of graft failure, mortality, and decline of graft function in…2020 American Transplant Congress
C-Reactive Protein 1-Year Post-Transplant is Associated with Future Development of Coronary Artery Vasculopathy and Rejection in a Pediatric Heart Transplant Cohort
Congenital Heart Center/Pediatrics, University of Florida, Gainesville, FL
*Purpose: Coronary artery vasculopathy (CAV) is one of the leading causes of mortality beyond 3y post-transplant (OHT). Multiple risk factors are associated with development of…2020 American Transplant Congress
Prospective Donor-Specific CellUlar Alloresponse Assessment for Immunosuppression MinImization in De Novo Renal Transplantation: Results of a Randomized Controlled Biomarker-Guided Trial
*Purpose: Early immunosuppression minimization is associated with higher rates of BPAR. Preformed donor-specific T-cell alloreactivity (DST) assessed with an IFN-γ ELISPOT assay has shown to…2020 American Transplant Congress
ATHENA – Patient and Allograft Outcome Differences after Kidney Transplantation – Germany vs. France
*Purpose: In the ATHENA trial [NCT01843348], efficacy and safety of everolimus in combination with tacrolimus [EVR+TAC] or cyclosporine A [EVR+CyA] vs. TAC and mycophenolic acid…2020 American Transplant Congress
HLA Molecular Mismatch is an Independent Correlate of T-Cell Mediated Rejection and Potential Prognostic Biomarker in Renal Transplantation
*Purpose: HLA molecular mismatch alloimmune risk categorization has correlated with de novo donor-specific antibody (dnDSA) development, however, correlation with T-cell mediated rejection (TCMR) phenotypes is…2020 American Transplant Congress
Clinical Significance of C4d and HLA-DSA on Post-Transplant Clinical Outcomes in Kidney Transplant Recipients with Antibody-Mediated Rejection
*Purpose: The clinicopathological diagnosis of rejection after kidney transplantation (KT) was well defined by Banff classification. In the diagnosis of antibody-mediated rejection (AMR), the presence…2020 American Transplant Congress
Single versus Dual Immunosuppression in Liver Transplantation for Autoimmune Liver Diseases
*Purpose: There is limited evidence on the optimal maintenance immunosuppression after liver transplant (LT) for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune…2020 American Transplant Congress
Influence of the Gut Microbiota on Acute Rejection of Vascular Allografts
Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
*Purpose: The gut microbiota influences immune responses in many ways but its involvement in transplant rejection is poorly understood. We have examined how changes in…2020 American Transplant Congress
Differences in Alemtuzumab Dosing Does Not Affect Early Kidney Transplant Outcomes
Wake Forest Baptist Health, Winston-Salem, NC
*Purpose: Alemtuzumab (Alem) is a widely used medication for induction therapy in kidney transplantation. However, there is limited evidence comparing outcomes with low versus high…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 172
- Next Page »